D. Ritchie

发表

Natural killer receptor ligand expression on acute myeloid leukemia impacts survival and relapse after chemotherapy.

M. Smyth, T. Perera, P. Blombery, 2018, Blood advances.

Immunotherapeutics in Multiple Myeloma: How Can Translational Mouse Models Help?

R. Koldej, Rachel E Cooke, D. Ritchie, 2019, Journal of oncology.

An atypical case of Epstein–Barr virus‐positive plasma cell post‐transplant lymphoproliferative disorder successfully treated with adoptive cell therapy

S. Avdic, A. Bajel, E. Blyth, 2021, British journal of haematology.

[18F]FDG-PET-CT compared with CT for persistent or recurrent neutropenic fever in high-risk patients (PIPPIN): a multicentre, open-label, phase 3, randomised, controlled trial.

J. Szer, R. Hicks, K. Thursky, 2022, The Lancet. Haematology.

P2X7 polymorphisms and stem cell mobilisation

R. Koldej, J. Collins, D. Ritchie, 2018, Leukemia.

Non-relapse cytopenias following allogeneic stem cell transplantation, a case based review

J. Szer, L. Chee, R. Koldej, 2022, Bone Marrow Transplantation.

Sorafenib priming may augment salvage chemotherapy in relapsed and refractory FLT3-ITD-positive acute myeloid leukemia

S. Jane, A. Wei, A. Bazargan, 2014, Blood Cancer Journal.

The improvement in overall survival from unrelated donor transplantation in Australia and New Zealand is driven by a reduction in non-relapse mortality: A study from the ABMTRR

G. Kennedy, A. Spencer, T. Perera, 2022, Bone Marrow Transplantation.

Nivolumab induces dynamic alterations in CD8 T-cell function and TIM-3 expression when used to treat relapsed acute myeloid leukemia after allogeneic stem cell transplantation

J. Szer, A. Grigg, R. Koldej, 2020, Leukemia & lymphoma.

Treatment approaches for patients with TP53-mutated mantle cell lymphoma.

C. Tam, A. Khot, J. Seymour, 2023, The Lancet. Haematology.

T cell receptor beta locus sequencing early post-allogeneic stem cell transplant identifies patients at risk of initial and recurrent cytomegalovirus infection

G. Ryland, D. Westerman, P. Blombery, 2021, Bone Marrow Transplantation.

Time-Limited Ibrutinib and Tisagenlecleucel Is Highly Effective in the Treatment of Patients with Relapsed or Refractory Mantle Cell Lymphoma, Including Those with TP53 Mutated and Btki-Refractory Disease: First Report of the Tarmac Study

S. Lade, C. Tam, C. Cheah, 2022, Blood.

Real‐world utility of early measurable residual disease assessments by multi‐parametric flow cytometry in adult patients with B‐lymphoblastic leukemia receiving Hyper‐CVAD induction chemotherapy

Ashley P Ng, S. Harrison, D. Westerman, 2022, European journal of haematology.

ALLG AMLM26 Phase 1B/2 Study Investigating Novel Therapies to Target Early Relapse and Clonal Evolution As Pre-Emptive Therapy in AML (INTERCEPT): A Multi-Arm, Precision-Based, Recursive, Platform Trial

M. Konopleva, K. Patel, D. Kipp, 2022, Blood.

Long-term outcomes for allogeneic bone marrow transplantation in Sezary syndrome and mycosis fungoides

H. Prince, A. Khot, G. Kennedy, 2022, Bone Marrow Transplantation.

BRUTON'S TYROSINE KINASE (BTK) INHIBITOR BGB‐3111 DEMONSTRATES HIGH VERY GOOD PARTIAL RESPONSE (VGPR) RATE IN PATIENTS WITH WALDENSTRÖM MACROGLOBULINEMIA (WM)

A. Roberts, S. Opat, C. Tam, 2017 .

Recommendation for TP53 mutation testing in newly diagnosed mantle cell lymphoma: a statement from working groups sponsored by the Victorian Comprehensive Cancer Centre

S. Opat, C. Tam, M. Gilbertson, 2022, Internal medicine journal.

A phase 1 clinical trial of the repurposable acetyllysine mimetic, n-methyl-2-pyrrolidone (NMP), in relapsed or refractory multiple myeloma

M. Ludford-Menting, C. Cheah, P. Galettis, 2023, Clinical Epigenetics.

Polymorphisms in Donor and Recipient p2x7 Receptor Predict Patient Outcome in Allogeneic Stem Cell Transplantation

T. Perera, R. Koldej, D. Ritchie, 2018 .

Predictors and outcomes of dose reduction of methotrexate and cyclosporin graft‐versus‐host disease prophylaxis following allogeneic haemopoietic cell transplantation

J. Szer, A. Bajel, R. Barmanray, 2022, Internal medicine journal.

Comparison of gene expression and flow cytometry for immune profiling in chronic lymphocytic leukaemia.

C. Tam, K. Mason, R. Koldej, 2018, Journal of immunological methods.

Dysregulation of immune cell and cytokine signalling correlates with clinical outcomes in myelodysplastic syndrome (MDS)

M. Ludford-Menting, L. Chee, R. Koldej, 2021, European journal of haematology.

Effective CMV prophylaxis with high‐dose valaciclovir in allogeneic hematopoietic stem‐cell recipients at a high risk of CMV infection

J. Sasadeusz, M. Slavin, L. Chee, 2022, Transplant infectious disease : an official journal of the Transplantation Society.

Allogeneic stem cell transplantation achieves long-term remissions in mantle cell lymphoma, including in TP53-mutated disease

C. Tam, A. Khot, M. Dickinson, 2023, Leukemia & lymphoma.

A Phase Ib/II Trial of Combined BRAF and EGFR Inhibition in BRAF V600E Positive Metastatic Colorectal Cancer and Other Cancers: The EVICT (Erlotinib and Vemurafenib In Combination Trial) Study

P. Gibbs, J. Desai, S. Dawson, 2023, Clinical cancer research : an official journal of the American Association for Cancer Research.

Nephrotic syndrome as a complication of chronic graft‐versus‐host disease after allogeneic haemopoietic stem cell transplantation

J. Szer, A. Roberts, M. Lasica, 2016, Internal medicine journal.

Immune priming with nivolumab followed by nivolumab and rituximab in first-line treatment of follicular lymphoma: The phase 2 1st FLOR study.

Charmaine D. Smith, M. Gilbertson, S. Lee, 2021 .

Anti-thymocyte globulins capable of binding to T and B cells reduce graft-vs-host disease without increasing relapse

J. Storek, A. Grigg, J. Russell, 2013, Bone Marrow Transplantation.

The hyper-CVAD–rituximab chemotherapy programme followed by high-dose busulfan, melphalan and autologous stem cell transplantation produces excellent event-free survival in patients with previously untreated mantle cell lymphoma

J. Szer, A. Roberts, H. Prince, 2006, Annals of Hematology.

Diagnostic and therapeutic approach to persistent or recurrent fevers of unknown origin in adult stem cell transplantation and haematological malignancy

S. Kirsa, A. Upton, D. Ritchie, 2008, Internal medicine journal.

Natural killer receptor ligand expression on acute myeloid leukemia impacts survival and relapse after chemotherapy.

M. Smyth, T. Perera, P. Blombery, 2018, Blood advances.

Diagnosis and management of endothelial disorders following haematopoietic stem cell transplantation

J. Szer, I. Kerridge, Y. Panek-Hudson, 2023, Internal medicine journal.

Australia and New Zealand Transplant and Cellular Therapies COVID‐19 vaccination consensus position statement

P. Shaw, C. Tiley, R. MacIntyre, 2021, Internal medicine journal.